3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)
Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.
Zacks Investment Research7/27/2026Positive
MEDP
Medpace Holdings IncNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$15.94B
P/E Ratio
33.57
EPS
$17.01
Beta
1.15
52W High
$677.90
52W Low
$373.00
50-Day MA
$494.62
200-Day MA
$517.08
Dividend Yield
—
Profit Margin
17.70%
Forward P/E
34.25
PEG Ratio
3.16
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Fundamentals
| Revenue (TTM) | $2.78B |
| Gross Profit (TTM) | $2.01B |
| EBITDA | $611.20M |
| Operating Margin | 20.80% |
| Return on Equity | 162.10% |
| Return on Assets | 20.10% |
| Revenue/Share (TTM) | $98.47 |
| Book Value | $16.18 |
| Price-to-Book | 37.92 |
| Price-to-Sales (TTM) | 5.73 |
| EV/Revenue | 5.78 |
| EV/EBITDA | 26.30 |
| Quarterly Earnings Growth (YoY) | 37.10% |
| Quarterly Revenue Growth (YoY) | 17.20% |
| Shares Outstanding | $27.91M |
| Float | $22.35M |
| % Insiders | 19.88% |
| % Institutions | 89.23% |
Historical Volatility
HV 10-Day
76.28%
HV 20-Day
57.39%
HV 30-Day
53.16%
HV 60-Day
40.68%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($581.83 target)
1
Strong Buy3
Buy8
Hold1
SellLatest News
Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Investment Research7/24/2026Positive
Medpace: 'Buy' On Financial Metric Improvements And Solid Q2 2026 Earnings
Medpace Holdings remains a "Buy" as Q2 2026 showed broad metric improvement and an inflection point in growth trajectory. The company's net book-to-Bill ratio rebounded to 1.13x, and backlog conversion rate rose to 24.1%, signaling strong future revenue visibility. Revenue grew 17.2% YoY to $707.3M, with EPS of $4.25 beating expectations; full-year 2026 guidance was raised to $2.805B–$2.885B.
Seeking Alpha7/23/2026Positive
Medpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call Transcript
Medpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call Transcript
Seeking Alpha7/23/2026Neutral
Medpace Q2 Earnings Call Highlights
Medpace NASDAQ: MEDP reported double-digit growth in second-quarter revenue and earnings, while management described the business environment as strong and said lower cancellations helped drive record net bookings.
MarketBeat7/23/2026Positive
Medpace Holdings, Inc. Reports Second Quarter 2026 Results
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Results Revenue for the three months ended June 30, 2026 increased 17.2% to $707.3 million, compared to $603.3 million for the comparable prior-year period. On a constant currency basis, revenue for the second quarter of 2026 increased 17.2% compared to the second quarter of 2025. Backlog as of June 30, 2026 in.
Business Wire7/22/2026Neutral
Why Medpace (MEDP) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research7/22/2026Positive
CON vs. MEDP: Which Stock Is the Better Value Option?
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Zacks Investment Research7/15/2026Positive
Why Medpace (MEDP) Dipped More Than Broader Market Today
Medpace (MEDP) closed at $530.19 in the latest trading session, marking a -1.49% move from the prior day.
Zacks Investment Research7/13/2026Neutral
Medpace Growth Trends Show How CRO Demand Is Shifting in 2026
MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.
Zacks Investment Research7/7/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MEDP and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026